

```

<!--StartFragment-->RESULT 1                               SEQ ID No. 1
ADQ31356
ID    ADQ31356 standard; protein; 123 AA.
XX
AC    ADQ31356;
XX
DT    07-OCT-2004 (first entry)
XX
DE    Anti-trkC agonist antibody heavy chain variable region, SEQ ID 1.
XX
KW    Neuroprotective; Analgesic; Cytostatic; taxol-induced sensory neuropathy;
KW    allodynia; cancer; anti-trkC agonist antibody; trk C; heavy chain;
KW    variable region.
XX
OS    Synthetic.
XX
FH    Key                Location/Qualifiers
FT    Region            23..31
FT                                /note= "Kabat complementarity determining region (CDR)"
FT    Region            31..35
FT                                /note= "Chothia CDR"
FT    Region            50..66
FT                                /note= "Kabat/Chothia CDR"
FT    Region            96..113
FT                                /note= "Kabat/Chothia CDR"
XX
PN    WO2004058190-A2.
XX
PD    15-JUL-2004.
XX
PF    23-DEC-2003; 2003WO-US041367.
XX
PR    23-DEC-2002; 2002US-0436147P.
XX
PA    (RINA-) RINAT NEUROSCIENCE CORP.
XX
PI    Shelton DL;
XX
DR    WPI; 2004-525789/50.
XX
PT    Treating taxol-induced sensory neuropathy (e.g. allodynia) in an
PT    individual comprises administering to the individual an amount of an anti
PT    -trkC agonist antibody.
XX
PS    Disclosure; Page 24; 68pp; English.
XX
CC    The present invention relates to a method for treating taxol-induced
CC    sensory neuropathy (e.g. allodynia) or cancer in an individual. The
CC    method comprises administering to the individual anti-trkC agonist
CC    antibody, which binds an epitope in domain 4 of human trk C. The present
CC    sequence is the heavy chain variable region of the anti-trkC agonist
CC    antibody.
XX
SQ    Sequence 123 AA;

Query Match                100.0%; Score 658; DB 1; Length 123;
Best Local Similarity      100.0%;
Matches 123; Conservative    0; Mismatches    0; Indels    0; Gaps    0;

Qy      1 QVQLVQSGAEVKKPGASVKVSKASGYTFTSYRIHWVRQAPGQGLEWMGEIYPSNARTNY 60
        |||||||
Db      1 QVQLVQSGAEVKKPGASVKVSKASGYTFTSYRIHWVRQAPGQGLEWMGEIYPSNARTNY 60

Qy      61 NEKFKSRVTMTDSTSTVYMESSLRSEDVAVYYCARKYYYYGNTRRSWYFDVWGQGTTV 120

```

```

|||||
Db      61 NEKFKSRVIMTRDTSTSTVYMEISSLRSEDYAVYYCARKYYYGNTRRSWYFDVWGQGTIV 120
Qy      121 TVS 123
        |||
Db      121 TVS 123

<!--EndFragment-->

```

```

<!--StartFragment-->RESULT 1
ADQ31357                               SEQ ID No. 2
ID   ADQ31357 standard; protein; 113 AA.
XX
AC   ADQ31357;
XX
DT   07-OCT-2004 (first entry)
XX
DE   Anti-trkC agonist antibody light chain variable region, SEQ ID 2.
XX
KW   Neuroprotective; Analgesic; Cytostatic; taxol-induced sensory neuropathy;
KW   allodynia; cancer; anti-trkC agonist antibody; trk C; light chain;
KW   variable region.
XX
OS   Synthetic.
XX
FH   Key                Location/Qualifiers
FT   Region             24..38
FT                       /note= "Kabat/ Chothia complementarity determining region
FT                       (CDR)"
FT   Region             54..60
FT                       /note= "Kabat/ Chothia CDR"
FT   Region             93..101
FT                       /note= "Kabat/ Chothia CDR"
XX
PN   WO2004058190-A2.
XX
PD   15-JUL-2004.
XX
PF   23-DEC-2003; 2003WO-US041367.
XX
PR   23-DEC-2002; 2002US-0436147P.
XX
PA   (RINA-) RINAT NEUROSCIENCE CORP.
XX
PI   Shelton DL;
XX
DR   WPI; 2004-525789/50.
XX
PT   Treating taxol-induced sensory neuropathy (e.g. allodynia) in an
PT   individual comprises administering to the individual an amount of an anti
PT   -trkC agonist antibody.
XX
PS   Disclosure; Page 24; 68pp; English.
XX
CC   The present invention relates to a method for treating taxol-induced
CC   sensory neuropathy (e.g. allodynia) or cancer in an individual. The
CC   method comprises administering to the individual anti-trkC agonist
CC   antibody, which binds an epitope in domain 4 of human trk C. The present
CC   sequence is the light chain variable region of the anti-trkC agonist
CC   antibody.
XX
SQ   Sequence 113 AA;

```

```

Query Match          100.0%; Score 581; DB 1; Length 113;
Best Local Similarity 100.0%;
Matches 113; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

Qy      1 DIQMTQSPSSLSASVGDRTITCRASESIDNYGISFLAWYQQKPGKAPKLLIYAASNRGS 60
          |||
Db      1 DIQMTQSPSSLSASVGDRTITCRASESIDNYGISFLAWYQQKPGKAPKLLIYAASNRGS 60
          |||
Qy      61 GVPSRFRSGSGSGTDFFTFTISLQPEDIATYYCQSQSKTPRTFGQGTKLEIKRT 113
          |||

```

Db 61 GVP5RFSGSGSGTDFTFTISSLQPEDATYYCQSKTVPRTFGQGTKLEIKRT 113

<!--EndFragment-->

```

<!--StartFragment-->RESULT 3
ADQ31356
ID ADQ31356 standard; protein; 123 AA. SEQ ID No. 4
XX
AC ADQ31356;
XX
DT 07-OCT-2004 (first entry)
XX
DE Anti-trkC agonist antibody heavy chain variable region, SEQ ID 1.
XX
KW Neuroprotective; Analgesic; Cytostatic; taxol-induced sensory neuropathy;
KW allodynia; cancer; anti-trkC agonist antibody; trk C; heavy chain;
KW variable region.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT Region 23. .31
FT /note= "Kabat complementarity determining region (CDR)"
FT Region 31. .35
FT /note= "Chothia CDR"
FT Region 50. .66
FT /note= "Kabat/Chothia CDR"
FT Region 96. .113
FT /note= "Kabat/Chothia CDR"
XX
PN WO2004058190-A2.
XX
PD 15-JUL-2004.
XX
PF 23-DEC-2003; 2003WO-US041367.
XX
PR 23-DEC-2002; 2002US-0436147P.
XX
PA (RINA-) RINAT NEUROSCIENCE CORP.
XX
PI Shelton DL;
XX
DR WPI; 2004-525789/50.
XX
PT Treating taxol-induced sensory neuropathy (e.g. allodynia) in an
PT individual comprises administering to the individual an amount of an anti
PT -trkC agonist antibody.
XX
PS Disclosure; Page 24; 68pp; English.
XX
CC The present invention relates to a method for treating taxol-induced
CC sensory neuropathy (e.g. allodynia) or cancer in an individual. The
CC method comprises administering to the individual anti-trkC agonist
CC antibody, which binds an epitope in domain 4 of human trk C. The present
CC sequence is the heavy chain variable region of the anti-trkC agonist
CC antibody.
XX
SQ Sequence 123 AA;

Query Match 100.0%; Score 10; DB 1; Length 123;
Best Local Similarity 100.0%;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 GYTFTSYRIH 10
   |||||
Db 26 GYTFTSYRIH 35
<!--EndFragment-->

```

```

<!--StartFragment-->RESULT 3
ADQ31356                               SEQ ID No. 5
ID   ADQ31356 standard; protein; 123 AA.
XX
AC   ADQ31356;
XX
DT   07-OCT-2004 (first entry)
XX
DE   Anti-trkC agonist antibody heavy chain variable region, SEQ ID 1.
XX
KW   Neuroprotective; Analgesic; Cytostatic; taxol-induced sensory neuropathy;
KW   allodynia; cancer; anti-trkC agonist antibody; trk C; heavy chain;
KW   variable region.
XX
OS   Synthetic.
XX
FH   Key                Location/Qualifiers
FT   Region             23..31
FT                       /note= "Kabat complementarity determining region (CDR)"
FT   Region             31..35
FT                       /note= "Chothia CDR"
FT   Region             50..66
FT                       /note= "Kabat/Chothia CDR"
FT   Region             96..113
FT                       /note= "Kabat/Chothia CDR"
XX
PN   WO2004058190-A2.
XX
PD   15-JUL-2004.
XX
PF   23-DEC-2003; 2003WO-US041367.
XX
PR   23-DEC-2002; 2002US-0436147P.
XX
PA   (RINA-) RINAT NEUROSCIENCE CORP.
XX
PI   Shelton DL;
XX
DR   WPI; 2004-525789/50.
XX
PT   Treating taxol-induced sensory neuropathy (e.g. allodynia) in an
PT   individual comprises administering to the individual an amount of an anti
PT   -trkC agonist antibody.
XX
PS   Disclosure; Page 24; 68pp; English.
XX
CC   The present invention relates to a method for treating taxol-induced
CC   sensory neuropathy (e.g. allodynia) or cancer in an individual. The
CC   method comprises administering to the individual anti-trkC agonist
CC   antibody, which binds an epitope in domain 4 of human trk C. The present
CC   sequence is the heavy chain variable region of the anti-trkC agonist
CC   antibody.
XX
SQ   Sequence 123 AA;

Query Match                100.0%; Score 17; DB 1; Length 123;
Best Local Similarity      100.0%;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 EIYPSNARTNYNEKFKS 17
        |||
Db      50 EIYPSNARTNYNEKFKS 66

<!--EndFragment-->

```

```

<!--StartFragment-->RESULT 3
ADQ31356
ID ADQ31356 standard; protein; 123 AA. SEQ ID No. 6
XX
AC ADQ31356;
XX
DT 07-OCT-2004 (first entry)
XX
DE Anti-trkC agonist antibody heavy chain variable region, SEQ ID 1.
XX
KW Neuroprotective; Analgesic; Cytostatic; taxol-induced sensory neuropathy;
KW allodynia; cancer; anti-trkC agonist antibody; trk C; heavy chain;
KW variable region.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT Region 23. .31
FT /note= "Kabat complementarity determining region (CDR)"
FT Region 31. .35
FT /note= "Chothia CDR"
FT Region 50. .66
FT /note= "Kabat/Chothia CDR"
FT Region 96. .113
FT /note= "Kabat/Chothia CDR"
XX
PN WO2004058190-A2.
XX
PD 15-JUL-2004.
XX
PF 23-DEC-2003; 2003WO-US041367.
XX
PR 23-DEC-2002; 2002US-0436147P.
XX
PA (RINA-) RINAT NEUROSCIENCE CORP.
XX
PI Shelton DL;
XX
DR WPI; 2004-525789/50.
XX
PT Treating taxol-induced sensory neuropathy (e.g. allodynia) in an
PT individual comprises administering to the individual an amount of an anti
PT -trkC agonist antibody.
XX
PS Disclosure; Page 24; 68pp; English.
XX
CC The present invention relates to a method for treating taxol-induced
CC sensory neuropathy (e.g. allodynia) or cancer in an individual. The
CC method comprises administering to the individual anti-trkC agonist
CC antibody, which binds an epitope in domain 4 of human trk C. The present
CC sequence is the heavy chain variable region of the anti-trkC agonist
CC antibody.
XX
SQ Sequence 123 AA;

Query Match 100.0%; Score 15; DB 1; Length 123;
Best Local Similarity 100.0%;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KYYGNTRRSWYFDV 15
| | | | | | | | | | | | | | |
Db 99 KYYGNTRRSWYFDV 113

<!--EndFragment-->

```

```

<!--StartFragment-->RESULT 3
ADQ31357
ID ADQ31357 standard; protein; 113 AA.
XX
AC ADQ31357;
XX
DT 07-OCT-2004 (first entry)
XX
DE Anti-trkC agonist antibody light chain variable region, SEQ ID 2.
XX
KW Neuroprotective; Analgesic; Cytostatic; taxol-induced sensory neuropathy;
KW allodynia; cancer; anti-trkC agonist antibody; trk C; light chain;
KW variable region.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT Region 24. .38
FT /note= "Kabat/ Chothia complementarity determining region
FT (CDR)"
FT Region 54. .60
FT /note= "Kabat/ Chothia CDR"
FT Region 93. .101
FT /note= "Kabat/ Chothia CDR"
XX
PN WO2004058190-A2.
XX
PD 15-JUL-2004.
XX
PF 23-DEC-2003; 2003WO-US041367.
XX
PR 23-DEC-2002; 2002US-0436147P.
XX
PA (RINA-) RINAT NEUROSCIENCE CORP.
XX
PI Shelton DL;
XX
DR WPI; 2004-525789/50.
XX
PT Treating taxol-induced sensory neuropathy (e.g. allodynia) in an
PT individual comprises administering to the individual an amount of an anti
PT -trkC agonist antibody.
XX
PS Disclosure; Page 24; 68pp; English.
XX
CC The present invention relates to a method for treating taxol-induced
CC sensory neuropathy (e.g. allodynia) or cancer in an individual. The
CC method comprises administering to the individual anti-trkC agonist
CC antibody, which binds an epitope in domain 4 of human trk C. The present
CC sequence is the light chain variable region of the anti-trkC agonist
CC antibody.
XX
SQ Sequence 113 AA;

Query Match 100.0%; Score 15; DB 1; Length 113;
Best Local Similarity 100.0%;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RASESIDNYGISFLA 15
| | | | | | | | | | | | | | |
Db 24 RASESIDNYGISFLA 38

<!--EndFragment-->

```



```

<!--StartFragment-->RESULT 4
ADQ31357
ID ADQ31357 standard; protein; 113 AA.
XX
AC ADQ31357;
XX
DT 07-OCT-2004 (first entry)
XX
DE Anti-trkC agonist antibody light chain variable region, SEQ ID 2.
XX
KW Neuroprotective; Analgesic; Cytostatic; taxol-induced sensory neuropathy;
KW allodynia; cancer; anti-trkC agonist antibody; trk C; light chain;
KW variable region.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT Region 24. .38
FT /note= "Kabat/ Chothia complementarity determining region
FT (CDR)"
FT Region 54. .60
FT /note= "Kabat/ Chothia CDR"
FT Region 93. .101
FT /note= "Kabat/ Chothia CDR"
XX
PN WO2004058190-A2.
XX
PD 15-JUL-2004.
XX
PF 23-DEC-2003; 2003WO-US041367.
XX
PR 23-DEC-2002; 2002US-0436147P.
XX
PA (RINA-) RINAT NEUROSCIENCE CORP.
XX
PI Shelton DL;
XX
DR WPI; 2004-525789/50.
XX
PT Treating taxol-induced sensory neuropathy (e.g. allodynia) in an
PT individual comprises administering to the individual an amount of an anti
PT -trkC agonist antibody.
XX
PS Disclosure; Page 24; 68pp; English.
XX
CC The present invention relates to a method for treating taxol-induced
CC sensory neuropathy (e.g. allodynia) or cancer in an individual. The
CC method comprises administering to the individual anti-trkC agonist
CC antibody, which binds an epitope in domain 4 of human trk C. The present
CC sequence is the light chain variable region of the anti-trkC agonist
CC antibody.
XX
SQ Sequence 113 AA;

Query Match 100.0%; Score 7; DB 1; Length 113;
Best Local Similarity 100.0%;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AASNRGS 7
| | | | | | |
Db 54 AASNRGS 60
<!--EndFragment-->

```

```

<!--StartFragment-->RESULT 3
ADQ31357
ID ADQ31357 standard; protein; 113 AA. SEQ ID No. 9
XX
AC ADQ31357;
XX
DT 07-OCT-2004 (first entry)
XX
DE Anti-trkC agonist antibody light chain variable region, SEQ ID 2.
XX
KW Neuroprotective; Analgesic; Cytostatic; taxol-induced sensory neuropathy;
KW allodynia; cancer; anti-trkC agonist antibody; trk C; light chain;
KW variable region.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT Region 24. .38
FT /note= "Kabat/ Chothia complementarity determining region
FT (CDR)"
FT Region 54. .60
FT /note= "Kabat/ Chothia CDR"
FT Region 93. .101
FT /note= "Kabat/ Chothia CDR"
XX
PN WO2004058190-A2.
XX
PD 15-JUL-2004.
XX
PF 23-DEC-2003; 2003WO-US041367.
XX
PR 23-DEC-2002; 2002US-0436147P.
XX
PA (RINA-) RINAT NEUROSCIENCE CORP.
XX
PI Shelton DL;
XX
DR WPI; 2004-525789/50.
XX
PT Treating taxol-induced sensory neuropathy (e.g. allodynia) in an
PT individual comprises administering to the individual an amount of an anti
PT -trkC agonist antibody.
XX
PS Disclosure; Page 24; 68pp; English.
XX
CC The present invention relates to a method for treating taxol-induced
CC sensory neuropathy (e.g. allodynia) or cancer in an individual. The
CC method comprises administering to the individual anti-trkC agonist
CC antibody, which binds an epitope in domain 4 of human trk C. The present
CC sequence is the light chain variable region of the anti-trkC agonist
CC antibody.
XX
SQ Sequence 113 AA;

Query Match 100.0%; Score 9; DB 1; Length 113;
Best Local Similarity 100.0%;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QQSKTVPRT 9
| | | | | | | |
Db 93 QQSKTVPRT 101

<!--EndFragment-->

```

```

<!--StartFragment-->RESULT 2
US-10-549-441-1
; Sequence 1, Application US/10549441                      SEQ ID No. 1
; Publication No. US20070014786A1
; GENERAL INFORMATION:
; APPLICANT: Shelton, David L.
; TITLE OF INVENTION: METHODS FOR TREATING TAXOL-INDUCED GUT
; TITLE OF INVENTION: DISORDER
; FILE REFERENCE: 514712001600
; CURRENT APPLICATION NUMBER: US/10/549,441
; CURRENT FILING DATE: 2005-09-16
; PRIOR APPLICATION NUMBER: PCT/US2004/008865
; PRIOR FILING DATE: 2004-03-22
; PRIOR APPLICATION NUMBER: US 60/456,648
; PRIOR FILING DATE: 2003-03-20
; NUMBER OF SEQ ID NOS: 10
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 1
;   LENGTH: 123
;   TYPE: PRT
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic Construct
US-10-549-441-1

Query Match          100.0%;   Score 658;   DB 5;   Length 123;
Best Local Similarity 100.0%;
Matches 123; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1  QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYRIHWVRQAPGQGLEWMGEIYPSNARTNY 60
         |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      1  QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYRIHWVRQAPGQGLEWMGEIYPSNARTNY 60

Qy      61  NEKFKSRVIMTRDSTSTVYMESSLRSEDTAVYYCARKYYYYGNTRRSWYFDVWGQGTIV 120
         |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      61  NEKFKSRVIMTRDSTSTVYMESSLRSEDTAVYYCARKYYYYGNTRRSWYFDVWGQGTIV 120

Qy      121  TVS 123
         |||
Db      121  TVS 123

<!--EndFragment-->

```

```

<!--StartFragment-->RESULT 2
US-10-549-441-2
; Sequence 2, Application US/10549441                      SEQ ID No. 2
; Publication No. US20070014786A1
; GENERAL INFORMATION:
; APPLICANT: Shelton, David L.
; TITLE OF INVENTION: METHODS FOR TREATING TAXOL-INDUCED GUT
; TITLE OF INVENTION: DISORDER
; FILE REFERENCE: 514712001600
; CURRENT APPLICATION NUMBER: US/10/549,441
; CURRENT FILING DATE: 2005-09-16
; PRIOR APPLICATION NUMBER: PCT/US2004/008865
; PRIOR FILING DATE: 2004-03-22
; PRIOR APPLICATION NUMBER: US 60/456,648
; PRIOR FILING DATE: 2003-03-20
; NUMBER OF SEQ ID NOS: 10
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 2
; LENGTH: 113
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Construct
US-10-549-441-2

Query Match          100.0%; Score 581; DB 5; Length 113;
Best Local Similarity 100.0%;
Matches 113; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1  DIQMTQSPSSLSASVGDRTVITCRASESIDNYGISFLAWYQQKPKGKAPKLLIYAASNRGS 60
      ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      1  DIQMTQSPSSLSASVGDRTVITCRASESIDNYGISFLAWYQQKPKGKAPKLLIYAASNRGS 60

Qy      61  GVPSRFGSGSGGTDFTFTISSLQPEDATYYCQQSKTVPRTFGQGTKLEIKRT 113
      ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      61  GVPSRFGSGSGGTDFTFTISSLQPEDATYYCQQSKTVPRTFGQGTKLEIKRT 113
<!--EndFragment-->

```

```

<!--StartFragment-->RESULT 1
US-10-549-441-3
; Sequence 3, Application US/10549441
; Publication No. US20070014786A1
; GENERAL INFORMATION:
; APPLICANT: Shelton, David L.
; TITLE OF INVENTION: METHODS FOR TREATING TAXOL-INDUCED GUT
; TITLE OF INVENTION: DISORDER
; FILE REFERENCE: 514712001600
; CURRENT APPLICATION NUMBER: US/10/549,441
; CURRENT FILING DATE: 2005-09-16
; PRIOR APPLICATION NUMBER: PCT/US2004/008865
; PRIOR FILING DATE: 2004-03-22
; PRIOR APPLICATION NUMBER: US 60/456,648
; PRIOR FILING DATE: 2003-03-20
; NUMBER OF SEQ ID NOS: 10
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 3
; LENGTH: 13
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Construct
US-10-549-441-3

Query Match          100.0%; Score 10; DB 5; Length 13;
Best Local Similarity 100.0%;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy          1 GYTFTSYRIH 10
             |||
Db          4 GYTFTSYRIH 13
<!--EndFragment-->

```

```

<!--StartFragment-->RESULT 1
US-10-549-441-4
; Sequence 4, Application US/10549441
; Publication No. US20070014786A1
; GENERAL INFORMATION:
; APPLICANT: Shelton, David L.
; TITLE OF INVENTION: METHODS FOR TREATING TAXOL-INDUCED GUT
; TITLE OF INVENTION: DISORDER
; FILE REFERENCE: 514/12001600
; CURRENT APPLICATION NUMBER: US/10/549,441
; CURRENT FILING DATE: 2005-09-16
; PRIOR APPLICATION NUMBER: PCT/US2004/008865
; PRIOR FILING DATE: 2004-03-22
; PRIOR APPLICATION NUMBER: US 60/456,648
; PRIOR FILING DATE: 2003-03-20
; NUMBER OF SEQ ID NOS: 10
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 4
; LENGTH: 17
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Construct
US-10-549-441-4

Query Match          100.0%; Score 17; DB 5; Length 17;
Best Local Similarity 100.0%;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 EIIYPSNARTNYNEKFKS 17
        |||
Db      1 EIIYPSNARTNYNEKFKS 17
<!--EndFragment-->

```

```

<!--StartFragment-->RESULT 1
US-10-549-441-5
; Sequence 5, Application US/10549441
; Publication No. US20070014786A1
; GENERAL INFORMATION:
; APPLICANT: Shelton, David L.
; TITLE OF INVENTION: METHODS FOR TREATING TAXOL-INDUCED GUT
; TITLE OF INVENTION: DISORDER
; FILE REFERENCE: 514712001600
; CURRENT APPLICATION NUMBER: US/10/549,441
; CURRENT FILING DATE: 2005-09-16
; PRIOR APPLICATION NUMBER: PCT/US2004/008865
; PRIOR FILING DATE: 2004-03-22
; PRIOR APPLICATION NUMBER: US 60/456,648
; PRIOR FILING DATE: 2003-03-20
; NUMBER OF SEQ ID NOS: 10
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 5
; LENGTH: 18
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Construct
US-10-549-441-5

Query Match          100.0%; Score 15; DB 5; Length 18;
Best Local Similarity 100.0%;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 KYYYGNTRRSWYFDV 15
        |||
Db      4 KYYYGNTRRSWYFDV 18
<!--EndFragment-->

```

```

<!--StartFragment-->RESULT 1
US-10-549-441-6
; Sequence 6, Application US/10549441
; Publication No. US20070014786A1
; GENERAL INFORMATION:
; APPLICANT: Shelton, David L.
; TITLE OF INVENTION: METHODS FOR TREATING TAXOL-INDUCED GUT
; TITLE OF INVENTION: DISORDER
; FILE REFERENCE: 514712001600
; CURRENT APPLICATION NUMBER: US/10/549,441
; CURRENT FILING DATE: 2005-09-16
; PRIOR APPLICATION NUMBER: PCT/US2004/008865
; PRIOR FILING DATE: 2004-03-22
; PRIOR APPLICATION NUMBER: US 60/456,648
; PRIOR FILING DATE: 2003-03-20
; NUMBER OF SEQ ID NOS: 10
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 6
; LENGTH: 15
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Construct
US-10-549-441-6

Query Match          100.0%; Score 15; DB 5; Length 15;
Best Local Similarity 100.0%;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 RASESIDNYGISFLA 15
        |||
Db      1 RASESIDNYGISFLA 15
<!--EndFragment-->

```



```

<!--StartFragment-->RESULT 1
US-10-549-441-7
; Sequence 7, Application US/10549441
; Publication No. US20070014786A1
; GENERAL INFORMATION:
; APPLICANT: Shelton, David L.
; TITLE OF INVENTION: METHODS FOR TREATING TAXOL-INDUCED GUT
; TITLE OF INVENTION: DISORDER
; FILE REFERENCE: 514712001600
; CURRENT APPLICATION NUMBER: US/10/549,441
; CURRENT FILING DATE: 2005-09-16
; PRIOR APPLICATION NUMBER: PCT/US2004/008865
; PRIOR FILING DATE: 2004-03-22
; PRIOR APPLICATION NUMBER: US 60/456,648
; PRIOR FILING DATE: 2003-03-20
; NUMBER OF SEQ ID NOS: 10
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 7
; LENGTH: 7
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Construct
US-10-549-441-7

Query Match      100.0%; Score 7; DB 5; Length 7;
Best Local Similarity 100.0%;
Matches      7; Conservative      0; Mismatches      0; Indels      0; Gaps      0;

Qy      1 AASNRGS 7
        |||||
Db      1 AASNRGS 7
<!--EndFragment-->

```

```

<!--StartFragment-->RESULT 1
US-10-549-441-8
; Sequence 8, Application US/10549441
; Publication No. US20070014786A1
; GENERAL INFORMATION:
; APPLICANT: Shelton, David L.
; TITLE OF INVENTION: METHODS FOR TREATING TAXOL-INDUCED GUT
; TITLE OF INVENTION: DISORDER
; FILE REFERENCE: 514712001600
; CURRENT APPLICATION NUMBER: US/10/549,441
; CURRENT FILING DATE: 2005-09-16
; PRIOR APPLICATION NUMBER: PCT/US2004/008865
; PRIOR FILING DATE: 2004-03-22
; PRIOR APPLICATION NUMBER: US 60/456,648
; PRIOR FILING DATE: 2003-03-20
; NUMBER OF SEQ ID NOS: 10
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 8
; LENGTH: 9
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Construct
US-10-549-441-8

Query Match          100.0%; Score 9; DB 5; Length 9;
Best Local Similarity 100.0%;
Matches      9; Conservative      0; Mismatches      0; Indels      0; Gaps      0;

Qy          1 QQSKTVPRT 9
            |||||
Db          1 QQSKTVPRT 9
<!--EndFragment-->

```